(2026). Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study. Cancer Medicine.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study."
Cancer Medicine 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study."
Cancer Medicine, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.